BLRX - BioLineRx Ltd.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
-0.0500 (-3.23%)
At close: 04:00PM EDT
1.5000 0.00 (0.00%)
After hours: 06:18PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
Previous Close1.5500
Bid1.4100 x 1000
Ask1.5500 x 1000
Day's Range1.3900 - 1.5600
52 Week Range0.5500 - 1.9800
Avg. Volume506,740
Market Cap92.296M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for BLRX

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • InvestorPlace

    7 High-Potential Penny Stocks in the Biotech Sector

    Most of the biggest biotech stocks on the market started off as unknown penny stocks. Look at Axsome Therapeutics (NASDAQ:AXSM), for example. At one time, it was a $2.50 stock. Now it’s up to $71 with a treatment for major depressive disorder. Fate Therapeutics (NASDAQ:FATE) once traded at less than $2.50, and ran to more than $114. Novavax (NASDAQ:NVAX) once traded around $3. All of them started small, but their strong pipelines didn’t let them stay cheap for long. In fact, find a biotech with

  • InvestorPlace

    The 3 Best Biotech Stocks Under $1 to Buy for April

    Typically, penny stocks are pure market wages for hardened gamblers. In fact, penny stocks are always risky — especially some of the best biotech stocks under $1 – and should oftentimes be avoided. And, as pointed out by the U.S. Securities and Exchange Commission (SEC), “Penny stocks may trade infrequently – which means that it may be difficult to sell penny stock shares once you have them. Because it may also be difficult to find quotations for penny stocks, they may be impossible to accuratel

  • Insider Monkey

    BioLineRx Ltd. (NASDAQ:BLRX) Q4 2022 Earnings Call Transcript

    BioLineRx Ltd. (NASDAQ:BLRX) Q4 2022 Earnings Call Transcript March 22, 2023 Operator: Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx 2022 Financial Results Conference Call. I would now like to turn over the call to John Lacey, Head of Investor Relations and Corporate Communications BioLineRx. Please go ahead. John Lacey: Thank […]

  • Benzinga

    BioLineRx Highlights Early-Stage Trial Data From Cancer Vaccine Candidate

    BioLineRx Ltd (NASDAQ: BLRX) announced results from the Phase 1/2a study of the intratumoral cancer vaccine candidate AGI-134 in patients with unresectable metastatic solid tumors. The study met its primary endpoint of AGI-134's safety and tolerability. In this first-in-human trial, 38 patients were treated with AGI-134. Part 1 demonstrated that AGI-134 was safe and well tolerated, with no dose-limiting toxicities reported. The maximum tolerated dose was not reached, and the recommended dose for

  • Benzinga

    BioLineRx Secures $40M In Debt Financing To Fund Commercialization Of Stem Cell Mobilization For Blood Cancer

    BioLineRx Ltd (NASDAQ: BLRX) entered into a $40 million non-dilutive secured debt financing agreement with Kreos Capital. Per the terms of the agreement, the first tranche of $10 million was made available to BioLineRx upon execution of the definitive agreement. The remaining $30 million will be made available in two additional tranches subject to achieving pre-specified milestones. The tranches are available for drawdown at BioLineRx's discretion at various time points through October 1, 2024.